Complications of inappropriate use of spironolactone in heart failure: When an old medicine spirals out of new guidelines

Journal of the American College of Cardiology

Volumn 41, Issue 2, 2003, Pages 211-214

  Bozkurt, Biykem ^a   Agoston, Ildiko ^a   Knowlton, A A ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; FEMALE; HEART BLOCK; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPONATREMIA; HYPOTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

AGED; ALDOSTERONE ANTAGONISTS; GUIDELINE ADHERENCE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERKALEMIA; HYPONATREMIA; HYPOTENSION; MALE; MIDDLE AGED; PATIENT SELECTION; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; SPIRONOLACTONE;

EID: 0037438820     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02694-3     Document Type: Article

References (13)

1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
2. Margo KL, Luttermoser G, Shaughnessy AF. Spironolactone in left-sided heart failure: how does it fit in? Am Fam Physician 2001;64:1393-8.
3. Kermani M, Dua A, Gradman AH. Underutilization and clinical benefits of angiotensin-converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction. Am J Cardiol 2000;86:644-8.
4. Eichhorn EJ. Experience with beta blockers in heart failure mortality trials. Clin Cardiol 1999;22 Suppl 5:V21-9.
5. Fielding LP, Grace R, Hittinger R. Limitations of randomised controlled trials. Br Med J 1995;310:1410.
6. Ghali WA, Cornuz J. Early uptake of research findings after fast-track publication. Lancet 2000;355:579-80.
7. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult. Circulation 2001;104:2996-3007.
8. Dutka M, Dzielski T, Wojciechowska J, Heller L, Trybus M. [Drug-related hyperkalemia resulted from spironolactone and angiotensin converting enzyme inhibitors therapy]. Pol Merkuriusz Lek 1999;7:69-70.
9. Berry C, McMurray JJ. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 2001;85:E8.
10. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001;110:438-41.
11. Philbin EF, Weil HF, Erb TA, Jenkins PL. Cardiology or primary care for heart failure in the community setting: process of care and clinical outcomes. Chest 1999;116:346-54.
12. Kasper EK, Gerstenblith G, Hefter G, et al. A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. J Am Coll Cardiol 2002;39:471-80.
13. Reis SE, Holubkov R, Edmundowicz D, et al. Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. J Am Coll Cardiol 1997;30:733-8.